S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Revelation Biosciences Stock Forecast, Price & News

-0.07 (-6.31%)
(As of 07/1/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
3.71 million shs
Average Volume
2.44 million shs
Market Capitalization
$15.69 million
P/E Ratio
Dividend Yield
Price Target

Revelation Biosciences Stock Forecast (MarketRank)

Analyst Rating
3.00 Rating Score
1,053.8% Upside
$12.00 Price Target
Short Interest
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($0.57) to ($0.66) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.63 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Revelation Biosciences logo

About Revelation Biosciences (OTCMKTS:REVB)

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company is developing therapeutic product candidates, including REVTx-99a for the prevention or treatment of viral infections, including SARS-CoV-2, variants of SARS-CoV-2, Influenza A, Influenza B, parainfluenza, respiratory syncytial virus, rhinosinusitis, and others; REVTx-99b for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also developing lead diagnostic candidate, such as REVDx-501 to detect various respiratory viral infections. The company is headquartered in San Diego, California.

REVB Stock News Headlines

Revelation Biosciences GAAP EPS of -$0.47
Revelation Biosciences Inc (REVB)
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
$-2.13 million
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
($4.30) per share


Free Float
Market Cap
$15.69 million
Not Optionable

Revelation Biosciences Frequently Asked Questions

Should I buy or sell Revelation Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revelation Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Revelation Biosciences stock.
View analyst ratings for Revelation Biosciences
or view top-rated stocks.

What is Revelation Biosciences' stock price forecast for 2022?

1 brokers have issued 1 year price objectives for Revelation Biosciences' stock. Their REVB stock forecasts range from $12.00 to $12.00. On average, they expect Revelation Biosciences' share price to reach $12.00 in the next year. This suggests a possible upside of 1,053.8% from the stock's current price.
View analysts' price targets for Revelation Biosciences
or view top-rated stocks among Wall Street analysts.

How has Revelation Biosciences' stock price performed in 2022?

Revelation Biosciences' stock was trading at $22.52 at the beginning of the year. Since then, REVB shares have decreased by 95.4% and is now trading at $1.04.
View the best growth stocks for 2022 here

How were Revelation Biosciences' earnings last quarter?

Revelation Biosciences, Inc. (OTCMKTS:REVB) released its quarterly earnings data on Monday, May, 16th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.25.
View Revelation Biosciences' earnings history

Who are Revelation Biosciences' key executives?

Revelation Biosciences' management team includes the following people:
  • Mr. James M. Rolke, CEO & Director (Age 53, Pay $466.63k)
  • Mr. Chester Stanley Zygmont III, Chief Financial Officer (Age 42, Pay $366.64k)
  • Ms. Sandra Vedrick, VP of HR & Investor Relations
  • Ms. Carol Odle, Sr. Director of Clinical Projects

What other stocks do shareholders of Revelation Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revelation Biosciences investors own include Primo Water (PRMW), Almaden Minerals (AAU), AA (AATDF), American Assets Trust (AAT), Advance Auto Parts (AAP), AAON (AAON), Applied Optoelectronics (AAOI), Aaron's (AAN), American Airlines Group (AAL) and AAC Technologies (AACAY).

What is Revelation Biosciences' stock symbol?

Revelation Biosciences trades on the OTCMKTS under the ticker symbol "REVB."

How do I buy shares of Revelation Biosciences?

Shares of REVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revelation Biosciences' stock price today?

One share of REVB stock can currently be purchased for approximately $1.04.

How much money does Revelation Biosciences make?

Revelation Biosciences (OTCMKTS:REVB) has a market capitalization of $15.69 million.

How many employees does Revelation Biosciences have?

Revelation Biosciences employs 2 workers across the globe.

How can I contact Revelation Biosciences?

The official website for Revelation Biosciences is www.revbiosciences.com. The company can be reached via phone at 971-622-5800.

This page (OTCMKTS:REVB) was last updated on 7/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.